Efforts to create new antibiotics face significant hurdles: a Colorado senator's bill to give drug companies incentives has stalled, and a different type of treatment being researched in Boulder is years away from reaching patients.
Subscribe to continue reading this article.
Already subscribed? To log in, click here.
Originally Published:
